Immuno-oncology, Market

Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: ‘It doesn’t work’

Nektar Therapeutics’ pegylation strategy on IL-2 promised to resolve one of the thorniest hurdles in cancer R&D, inspiring a record $1.85 billion deal by a group of cancer research specialists at Bristol-Myers Squibb who were intensely excited by NKTR-214 and the prospect of advancing a killer approach to checkpoint combos.

But an analyst who’s played a key role behind some of the most effective short attacks in biotech in recent years has just fired a torpedo at the mother ship, hoping to persuade investors that NKTR-214 — one of the most closely followed cancer drugs now in the clinic — is absolutely worthless.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->